DiogenX strengthens its management team
The biotech company DiogenX, based in Marseille (F), has appointed Hélène Sicard, PhD, as Chief Development Officer.
ADVERTISEMENT
About Maren Kühr
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 189 entries already.
Entries by Maren Kühr
Experienced CEO appointed
Lori A. Ball has been appointed as the new Chief Executive Officer of UK-based Astoriom. She will be responsible for driving the development of Astoriom’s sample management business in the US, UK and Europe.
New Chief Scientific Officer
Cambridge-based Mogrify Ltd announces the appointment of Dr. Jonathan Appleby as Chief Scientific Officer.
Macomics expands leadership team
A new Chief Business Officer strengthens the management team of Macomics Ltd (UK). Simon Drew took over the newly created position in June.
Young biotech company recruits experienced CMO
At the end of May, Dr Uwe Meya took over as Chief Medical Officer at Oxford-based SynaptixBio.
IZB Start-up mk2
Mk2 Biotechnologies GmbH was founded in 2020 and is located in the Innovation and Start-up Centre IZB in Planegg-Martinsried.
Where has the conviction gone?
2023 was another particularly tumultuous year for life sciences and, although the lingering effects of the last year are unlikely to change dramatically, the stabilisation of interest rates (off 16-year highs) and emerging direction of travel (market data points) tilt our bias to positive for the new year.
Interims CEO takes over
In November 2023, Enhanc3D Genomics appointed Dr Hazel Jones as interim CEO and COO. Now she has taken over the Position of CEO officially.
Cancer research on three pillars
Over the past few years, the Frankfurt Institute of Clinical Cancer Research (IKF) has successfully conducted over 90 clinical studies. Each year, it enrolls approximately 1,500 patients in these trials. European Biotechnology spoke with the founder and director Prof. Dr med. Salah-Eddin Al-Batran.
The future of health biotech innovation in Europe
The 2023 State of the Union speech saw biotechnology rise as a priority for the European Union. It has been designated as a critical technology for Europe’s economic security. In March 2024, the European Commission presented its biotechnology and biomanufacturing strategy with a clear leadership ambition for Europe’s biotech industries. The Letta Report on the future of the Single Market, published April 2024, proposed a fifth freedom on research and innovation which would directly benefit biotech.